Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (European commission: Executive Agency for Small and Medium-sized Enterprises – EASME).

2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission


2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission


2015 17th i-Lab “Créadev” BPI France


2013 15th “émergence” OSEO/BPI


2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.

Contact Info

Parc scientifique Biocitech
102 Avenue Gaston Roussel
Batiment Pasteur Secteur 2169
93230 Romainville - France

56 Boulevard de la Mission Marchand - 92400 Courbevoie France

Phone: +33 1 43 34 89 90

Mobile: +33 6 60 90 41 24

10 07, 2019

2019 – Le Figaro Economie – RDV PME

July 10th, 2019|0 Comments

Regulaxis’ President Claude Carelli and the COO Christelle Vêtu participated to the RDV PME by Le Figaro Economie
This interview is focused on the research and development in the field of bioscience. In particular Regulaxis present a new innovative compound, REGO3, for the treatment of arthroses.


Follow the full article to Le Figaro Economie


30 05, 2019

2019 – Sendai, Japan – EU-Japan Industrial Cooperation

May 30th, 2019|0 Comments

Regulaxis is very proud to be the only French company selected by the EU-Japan Industrial Cooperation Center to be part of the European delegation !
Thank you also to Miyagi province officials and Jetro for receiving us and meeting top industrial companies in Sendai.


Dr. Matthieu Chareyre, our Executive Director of Industrial Operations, represented Regulaxis to this […]

8 04, 2019

2019 – Paris, France – ANRT – CLUB PME – ETI

April 8th, 2019|0 Comments

Lors de la séance du 8 Avril du CLUB PME – ETI Claude CARELLI, Président et CEO de Regulaxis a présenté son entreprise et son « business model ». Les membres du Club l’ont « challengé » pour qu’il récolte le fruit de ce «brainstorming » collectif.
Engagée dans la R&D, Regulaxis développe des molécules […]

10 12, 2018

2018 – Regulaxis moves to La Défense !

December 10th, 2018|0 Comments

The offices of the Regulaxis Management Office are located at the feet of La Défense, the business district located in the Metropole du Grand Paris.

15 06, 2018

2018 – Partnership between REGULAXIS and ARTIALIS

June 15th, 2018|0 Comments

REG-O3, the innovative therapeutic treatment for Osteoarthritis will be tested in Liège !:
Artialis, specialist in the study of the musculoskeletal disorders and Regulaxis, an innovative French company in the treatment of osteoarthritis, announce today the signing of a 1.6 million euros contract for the preclinical and clinical development of a new molecule, Reg-O3, allowing […]

1 05, 2017


May 1st, 2017|0 Comments

Regulaxis is proud to announce to receive € 2.1m from EU Horizon 2020 SME instrument Phase 2 program for early gonarthrosis (OA) therapeutic drug regenerating cartilage !

28 06, 2016

2016 – Romainville, France – BIOCITECHDAY

June 28th, 2016|0 Comments

Dr. Claude Carelli, President and CEO of REGULAXIS, presented to BIOCITECHDAY the innovative molecule under development for the therapeutic treatment of knee osteoarthritis.

1 07, 2015

2015 – Paris, France – I-LAB 2015

July 1st, 2015|0 Comments


Drs Christelle Vêtu and Claude Carelli are proud to announce that REGULAXIS has been awarded at the 17th National Contest for the Creation of Innovative Enterprises organized by the Ministry of Higher Education, Research and Innovation. The prize consists of a grant of € 200k.

18 04, 2014

2014 – Regulaxis in the French Magazine “Challenges”

April 18th, 2014|0 Comments

Regulaxis SAS is proud to announce that it has been selected by the economy newspaper Challenge in its issue of 17-23 April 2014 for the 2014 edition of its record of 100 French start-ups in which it is advisable to invest.

7 10, 2013

2013 – Paris, France – REGULAXIS at The Universal Biotech Innovation Prize

October 7th, 2013|0 Comments

The Universal Biotech Innovation Prize is open to Small and Medium Enterprises from Europe and China and to academics researchers on preventive and curative therapies, medical devices, technological tools.
Regulaxis project finished 15th on 81 companies  from 16 european countries at the the Universal Biotech Innovation Prize.